Biosensors International Group, Ltd.
BioMatrix Alpha - Model Biolimus A9 -Proven Safety of the Biolimus Drug
Low Late Loss: 9 month in stent late loss 0.13mm6. In Stent late loss in LEADERS = 0.13mm6.
Most popular related searches
Highest lipophilicity of the common limus drugs1
- Targeted Tissue Release
- PLA biodegradation along with BA9™ elution
- Complete resorption of PLA coating from the stent after 6-9 months